SS Innovations announced the completion of five new 5-mm surgical instruments to enhance robotic surgery for various specialties.
Quiver AI Summary
SS Innovations International, Inc. announced the completion of five new 5-millimeter surgical instruments designed for clinical use in various specialties, particularly pediatric, cardiac, and head and neck surgeries. These instruments, which include spatula and hook cauteries, a needle driver, bipolar forceps, and grasping forceps, aim to enhance robotic surgical procedures, especially for the pediatric population that currently lacks access to critical surgical care. The company highlights the urgent need for affordable robotic surgeries for children, as well as the advantages these smaller instruments provide in cardiac and head and neck procedures. As of December 31, 2025, SS Innovations has installed 168 SSi Mantra robotic systems and conducted over 7,800 surgical procedures across 153 hospitals, indicating a strong commitment to making advanced surgical technologies accessible globally.
Potential Positives
- Completion of five new 5-millimeter surgical instruments enhances the company's product offerings in pediatric, cardiac, and head and neck surgeries.
- The development of smaller instruments aims to address the significant gap in surgical care for the 1.7 billion children and adolescents lacking access to critical surgical interventions globally.
- SS Innovations reports a cumulative installed base of 168 SSi Mantra systems, indicating growing market adoption and successful deployment in multiple countries.
- The company has performed over 7,800 surgical procedures, demonstrating the practical application and effectiveness of its robotic technologies in real-world settings.
Potential Negatives
- While the company has developed new instruments, they have only installed 168 systems globally, which may indicate limited market penetration compared to competitors.
- The press release highlights the significant lack of access to surgical care for children worldwide, which could reflect poorly on the company's past performance and effectiveness in addressing this critical issue.
- There is a heavy reliance on forward-looking statements that invoke uncertainties and risks, which could raise concerns about the company's future financial stability and market prospects.
FAQ
What are the new surgical instruments developed by SS Innovations?
SS Innovations has developed five new 5-millimeter surgical instruments: spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps.
How do these instruments support pediatric surgery?
The newly developed instruments are designed to aid robotic procedures involving smaller anatomical structures, addressing the needs of pediatric patients.
What is the SSi Mantra surgical robotic system?
The SSi Mantra is a flexible, multi-arm robotic surgical system equipped with advanced technology, supporting various surgical specialties, including cardiac surgery.
How many surgical procedures have been performed using the SSi Mantra?
To date, over 7,800 surgical procedures have been performed with the SSi Mantra, including over 400 cardiac surgeries and 120 telesurgeries.
What is SS Innovations' mission regarding robotic surgery?
SS Innovations aims to make robotic surgery affordable and accessible to a broader global population, particularly for children and underserved communities.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SSII Hedge Fund Activity
We have seen 9 institutional investors add shares of $SSII stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HANDELSBANKEN FONDER AB added 109,802 shares (+inf%) to their portfolio in Q3 2025, for an estimated $713,713
- BARCLAYS PLC removed 66,759 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $433,933
- INSPIRE INVESTING, LLC added 36,887 shares (+inf%) to their portfolio in Q3 2025, for an estimated $239,765
- STATE STREET CORP added 15,900 shares (+inf%) to their portfolio in Q3 2025, for an estimated $103,350
- ENVESTNET ASSET MANAGEMENT INC added 10,982 shares (+inf%) to their portfolio in Q3 2025, for an estimated $71,383
- GEODE CAPITAL MANAGEMENT, LLC added 9,263 shares (+44.6%) to their portfolio in Q3 2025, for an estimated $60,209
- PNC FINANCIAL SERVICES GROUP, INC. added 8,627 shares (+inf%) to their portfolio in Q3 2025, for an estimated $56,075
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
FORT LAUDERDALE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII) , a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company has completed the development of five new 5-millimeter surgical instruments for clinical use across multiple specialties, including pediatric, cardiac, and head and neck surgery, among other procedures involving smaller anatomical structures.
The newly developed 5-millimeter surgical instruments include a spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps.
Dr. Vishwa Srivastava, the Company’s Chief Executive Officer for Asia Pacific, commented, “We developed several new smaller instruments designed to benefit critical surgical robotic procedures across multiple specialties, including pediatric, cardiac, and head and neck. Our innovative 5-millimeter instruments, combined with our advanced, cost-effective SSi Mantra surgical robotic system, show great promise for supporting the large population of pediatric patients left behind each year. Globally, 1.7 billion children and adolescents lack easy access to critical surgical care, which can play a significant role in preventing disability and death.
1
It has been reported that more than 390 million children under the age of five in lower- and middle-income countries do not receive timely intervention with safe and affordable surgical care.
2
Unfortunately, to date most robotic surgeries have been geared towards the adult population. We aim to make robotic surgery more accessible to pediatric patients with new, smaller surgical instruments.”
Dr. Srivastava concluded, “In addition, our 5-millimeter instruments can benefit cardiac surgery, which often involves small structures, such as the internal mammary artery during robotic coronary artery bypass surgery. Furthermore, our new robotic instruments can help perform critical tasks during head and neck procedures, which entail tight working space and quite small structures. Moving forward, we will continue to focus on developing differentiated surgical robotic technologies, such as these instruments, for the benefit of a larger segment of patients globally.”
As of December 31, 2025, the cumulative installed base of the SSi Mantra totaled 168 systems, including 12 systems deployed across nine countries outside of India. To date, 153 hospitals have installed the SSi Mantra, and more than 7,800 surgical procedures have been performed, including over 120 telesurgeries and more than 400 cardiac procedures.
1 Mullapudi, Bhargava, et al. “Estimates of Number of Children and Adolescents without Access to Surgical Care.” Bulletin of the World Health Organization , vol. 97, no. 4, 2019, pp. 254–58. PubMed Central , https://pmc.ncbi.nlm.nih.gov/articles/PMC6438256/ .
2 Wadhwani, Vidhi, and Siddhesh Zadey. “How Pediatric Surgery Could Help India Reach Its Development Goals.” Think Global Health , 14 Mar. 2024, https://www.thinkglobalhealth.org/article/how-pediatric-surgery-could-help-india-reach-its-development-goals .
About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of robotic surgical procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at
ssinnovations.com
or
LinkedIn
for more information and updates.
About the SSi Mantra
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.
Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Investor Contact:
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
[email protected]
Devin Sullivan, Managing Director
T: (212) 836-9608
[email protected]
Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
[email protected]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2f60846c-4568-4935-a282-63e5d405d75e